Evidence map›Paper›PMID 35233975›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2022

Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019.

Huibin Long, Qiang Liu, Heyong Yin, Kai Wang, Naicheng Diao, Yuqing Zhang, Jianhao Lin, Ai Guo

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 622 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
622citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06603662 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department

TypeinterventionalSponsorWellSpan HealthRan2025 to 2027Enrolled192ConditionsOsteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the HipArmsPrednisone, Dexamethasone, Placebo
NCT06792539 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

A Multi-Center, Prospective, Non-Randomized, Pivotal Trial Evaluating the Safety and Effectiveness of the Polymotion Hip Resurfacing System

TypeinterventionalSponsorJointMedica Inc.Ran2025 to 2028Enrolled238ConditionsOsteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia, HipArmsPolymotion Hip Resurfacing (PHR) System
NCT07439315 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis

TypeinterventionalSponsorIcarus Medical InnovationsRan2026 to 2026Enrolled150ConditionsMedial Compartment Knee OsteoarthritisArmsMedial joint distraction brace
3 · Its place in the literature

Who cites it

622 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. mSystems · 2025
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

562 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Huibin LongBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Qiang LiuPeking University People's Hospital, Peking University, Beijing, China.ORCID 0000-0003-3029-2625
Heyong YinBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Kai WangPeking University People's Hospital, Peking University, Beijing, China.
Naicheng DiaoBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Yuqing ZhangHarvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7638-0888
Jianhao LinPeking University People's Hospital, Peking University, Beijing, China.ORCID 0000-0003-1830-9244
Ai GuoBeijing Friendship Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate systematic and anatomic site-specific age-standardized prevalence rates (ASRs) and analyze the secular trends of osteoarthritis (OA) at global, regional, and national levels.

methodsData were derived from the Global Burden of Disease Study 2019. ASRs and their estimated annual percentage changes (EAPCs) were used to describe the secular trends of OA according to age group, sex, region, country, and territory, as well as the joints involved.

resultsGlobally, prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019. ASRs were 6,173.38 per 100,000 in 1990 and 6,348.25 per 100,000 in 2019, with an average annual increase of 0.12% (95% confidence interval [95% CI] 0.11%, 0.14%). The ASR of OA increased for the knee, hip, and other joints, but decreased for the hand, with EAPCs of 0.32 (95% CI 0.29, 0.34), 0.28 (95% CI 0.26, 0.31), 0.18 (95% CI 0.18, 0.19), and -0.36 (95% CI -0.38, -0.33), respectively. OA prevalence increased with age and revealed female preponderance, geographic diversity, and disparity with regard to anatomic site. OA of the knee contributed the most to the overall burden, while OA of the hip had the highest EAPC in most regions.

conclusionOA has remained a major public health concern worldwide over the past decades. The prevalence of OA has increased and diversified by geographic location and affected joint. Prevention and early treatment are pivotal to mitigating the growing burden of OA.

Indexed as

Global Burden of DiseaseOsteoarthritisFemaleHumansIncidenceKnee JointPrevalenceQuality-Adjusted Life Years

Identifiers

PMID35233975
PMCPMC9543105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.